Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TPX-4589 |
| Trade Name | |
| Synonyms | LM 302|LM302|LM-302|TPX 4589|TPX4589|Tecotabart vedotin |
| Drug Descriptions |
TPX-4589 (LM-302) is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2) targeted antibody linked to monomethyl auristatin E (MMAE), which potentially inhibits proliferation of CLDN18.2-expressing tumor cells and tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S41-S42). |
| DrugClasses | CLDN18.2 Antibody 23 |
| CAS Registry Number | NA |
| NCIT ID | C185853 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Toripalimab-tpzi + TPX-4589 | TPX-4589 Toripalimab-tpzi | 0 | 1 |
| TPX-4589 | TPX-4589 | 0 | 2 |